Table 8.
Forty most likely candidate drugs for glaucoma.
| Name | Medical uses | FDR |
|---|---|---|
| Alitretinoin | Chronic hand eczema (1) | 2.41E-03 |
| Vinblastine | Interference with tubulin (2) | 6.76E-05 |
| Paclitaxel | Non-small-cell lung cancer (3) | 2.41E-03 |
| Meptazinol | Analgesia (4) | 4.31E-05 |
| Caffeine | Neurodegenerative diseases (5) | 6.00E-07 |
| Auranofin | Rheumatoid arthritis (6) | 0 |
| Cilomilast | Asthma and chronic obstructive pulmonary disease (7) | 5.71E-04 |
| Dipyridamole | Antithrombosis (8) | 5.71E-04 |
| Loperamide | Acute infectious diarrhea (9) | 1.23E-03 |
| Ketotifen | Allergic diseases (10), chronic urticaria (11) | 2.41E-03 |
| Tipifarnib | Prevents hypoxia-induced pulmonary hypertension (12), tumor (13) | 0 |
| Pentoxifylline | Venous leg ulcer (14) | 0 |
| Aspirin | Antitumor (15), pain (16) | 0 |
| Sulfasalazine | Rheumatoid arthritis (17) | 4.00E-07 |
| Docetaxel | Breast cancer (18) | 2.27E-04 |
| Tretinoin | Acne vulgaris, keratosis pilaris, acute promyelocytic and leukemia (19) | 2.41E-03 |
| Celecoxib | Osteoarthritis, rheumatoid arthritis and ankylosing spondylitis (20) | 3.74E-02 |
| Retinol | Reduces symptoms of skin aging (21) | 3E-08 |
| Carvedilol | Systemic hypertension and myocardial dysfunction (22) | 1E-08 |
| Pyrazinamide | Tuberculosis (23) | 0 |
| Acitretin | Pediatric psoriasis (24) | 0 |
| Linifanib | Cancer (25) | 0 |
| Cytarabine | Acute myeloid leukemia (26) | 8E-08 |
| Sulpiride | Schizophrenia (27) | 1.41E-04 |
| Ocriplasmin | Symptomatic vitreomacular adhesion (28) | 0 |
| Bevacizumab | Recurrent glioblastoma (29) | 1.08E-04 |
| Dexamethasone | Acute spinal cord injury (30) | 0 |
| Cyclosporine | Transplant rejection (31) | 1.454-04 |
| Everolimus | Tumors (32) | 4.31E-02 |
| Fluorouracil | Tumors (33) | 2.23E-04 |
| Tamoxifen | Breast cancer (34) | 1.08E-04 |
| Etretinate | Psoriasis and many other skin diseases (35) | 0 |
| Trametinib | Melanoma (36) | 2.94E-04 |
| Selumetinib | Advanced/metastatic non-small-cell lung cancer (37) | 3.75E-04 |
| Sirolimus | Prevention of transplant rejection (38) | 1.45E-04 |
| Dasatinib | Chronic myeloid leukemia (39) | 5.98E-04 |
| Gemcitabine | Cancer (40) | 2.94E-04 |
| Cetuximab | Cancer (41) | 2.51E-04 |
| Arsenic trioxide | Acute promyelocytic leukemia (42) | 5.43E-04 |
| Labetalol | Hypertension (43) | 0 |